{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:39:22Z","timestamp":1787999962568,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We examined responsiveness to ripasudil as a potential factor for predicting the effect of selective laser trabeculoplasty (SLT) when performed for primary open-angle glaucoma (POAG). A total of 70 eyes with no history of glaucoma surgery underwent SLT between January 2015 and June 2019. Patients were divided into two groups, with an intraocular pressure (IOP) decrease of 15% or more due to ripasudil administration before SLT defined as the effective group, while an IOP decrease of less than 15% was defined as the non-effective group. Kaplan\u2013Meier survival analysis was performed. A Cox proportional hazards model assessed the influence of baseline factors on the success. Of the 70 eyes evaluated, treatments were effective in 22 and non-effective in 48. Postoperatively, both groups exhibited IOP reductions for up to 24\u00a0months. Success ratios at 12 and 24\u00a0months after SLT were 43.5% and 18.5% in the effective versus 24.9% and 9.3% in the non-effective group, which were significantly higher in the effective group (<jats:italic>P<\/jats:italic>\u2009=\u20090.03). Presence of a ripasudil effective eye (<jats:italic>P<\/jats:italic>\u2009=\u20090.03) was associated with treatment success. Responsiveness to ripasudil may be useful in predicting the therapeutic effect of SLT.<\/jats:p>","DOI":"10.1038\/s41598-021-85271-w","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T11:07:02Z","timestamp":1615547222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Responsiveness to ripasudil may be a potential outcome marker for selective laser trabeculoplasty in patients with primary open-angle glaucoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Taro","family":"Baba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Hirooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"85271_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley, H. A. & Broman, A. T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90, 262\u2013267 (2006).","journal-title":"Br. J. Ophthalmol."},{"key":"85271_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2013.05.002","volume":"37","author":"T Inoue","year":"2013","unstructured":"Inoue, T. & Tanihara, H. Rho-associated kinase inhibitors: A novel glaucoma therapy. Prog. Retin. Eye. Res. 37, 1\u201312 (2013).","journal-title":"Prog. Retin. Eye. Res."},{"key":"85271_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0014-4835(05)80093-4","volume":"60","author":"MA Latina","year":"1995","unstructured":"Latina, M. A. & Park, C. Selective targeting of trabecular meshwork cells: In vitro studies of pulsed and CW laser interactions. Exp. Eye. Res. 60, 359\u2013371 (1995).","journal-title":"Exp. Eye. Res."},{"key":"85271_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/eye.2017.273","volume":"32","author":"A Gang","year":"2018","unstructured":"Gang, A. & Gazzard, G. Selective laser trabeculoplasty: Past, present, and future. Eye (Lond). 32, 863\u2013876 (2018).","journal-title":"Eye (Lond)."},{"key":"85271_CR5","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bjo.2006.098855","volume":"90","author":"KF Damiji","year":"2006","unstructured":"Damiji, K. F. et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: Results from a 1-year randomised clinical trial. Br. J. Ophthalmol. 90, 1490\u20131494 (2006).","journal-title":"Br. J. Ophthalmol."},{"key":"85271_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/IJG.0b013e3181e3d2c1","volume":"20","author":"E Martow","year":"2011","unstructured":"Martow, E., Hutnik, C. M. L. & Mao, A. SLT and adjunctive medical therapy: A prediction rule analysis. J. Glaucoma. 20, 266\u2013270 (2011).","journal-title":"J. Glaucoma."},{"key":"85271_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/IJG.0000000000000411","volume":"25","author":"A Miki","year":"2016","unstructured":"Miki, A., Kawashima, R., Usui, S., Matsushita, K. & Nishida, K. Treatment outcomes and prognostic factors of selective lase trabeculoplasty for open-angle glaucoma receiving maximal-tolerable medical therapy. J. Glaucoma. 25, 785\u2013789 (2016).","journal-title":"J. Glaucoma."},{"key":"85271_CR8","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/01.ijg.0000176939.43681.c2","volume":"14","author":"J Song","year":"2005","unstructured":"Song, J. et al. High failure rate associated with 180 degrees selective laser trabeculoplasty. J. Glaucoma. 14, 400\u2013408 (2005).","journal-title":"J. Glaucoma."},{"key":"85271_CR9","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/j.ophtha.2014.07.017","volume":"121","author":"D Jinapriya","year":"2014","unstructured":"Jinapriya, D. et al. Anti-inflammatory therapy after selective laser trabeculoplasty: A randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 121, 2356\u20132361 (2014).","journal-title":"Ophthalmology"},{"key":"85271_CR10","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(18)32213-X","volume":"393","author":"G Gazzard","year":"2019","unstructured":"Gazzard, G. et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): A multicentre randomised controlled trial. Lancet 393, 1505\u20131516 (2019).","journal-title":"Lancet"},{"key":"85271_CR11","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/bjo.2004.062414","volume":"89","author":"WG Hodge","year":"2005","unstructured":"Hodge, W. G. et al. Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: Results from a randomised clinical trial. Br. J. Ophthalmol. 89, 1157\u20131160 (2005).","journal-title":"Br. J. Ophthalmol."},{"key":"85271_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/IJG.0000000000000049","volume":"23","author":"JW Lee","year":"2014","unstructured":"Lee, J. W., Liu, C. C., Chan, J. C. & Lai, J. S. Predictors of success in selective laser trabeculoplasty for Chinese open-angle glaucoma. J. Glaucoma. 23, 321\u2013325 (2014).","journal-title":"J. Glaucoma."},{"key":"85271_CR13","doi-asserted-by":"publisher","first-page":"9428","DOI":"10.1038\/s41598","volume":"10","author":"M Hirabayashi","year":"2020","unstructured":"Hirabayashi, M., Ponnusamy, V. & An, J. Predictive factors for outcomes of selective laser trabeculoplasty. Sci. Rep. 10, 9428. https:\/\/doi.org\/10.1038\/s41598 (2020).","journal-title":"Sci. Rep."},{"key":"85271_CR14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ophtha.2019.11.017","volume":"127","author":"AP Khawaja","year":"2020","unstructured":"Khawaja, A. P. et al. Real-world outcomes of selective laser trabeculoplasty in the United Kingdom. Ophthalmology 127, 748\u2013757 (2020).","journal-title":"Ophthalmology"},{"key":"85271_CR15","first-page":"137","volume":"42","author":"M Honjo","year":"2001","unstructured":"Honjo, M. et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest. Ophthalmol. Vis. Sci. 42, 137\u2013144 (2001).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"85271_CR16","first-page":"1029","volume":"42","author":"PV Rao","year":"2001","unstructured":"Rao, P. V., Deng, P. F., Kumar, J. & Epstein, D. L. Modulation of aqueous humor outflow facility by the rho kinase-specific inhibitor Y-27632. Invest. Ophthalmol. Vis. Sci. 42, 1029\u20131037 (2001).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"85271_CR17","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/S0161-6420(98)91129-0","volume":"105","author":"MA Latina","year":"1998","unstructured":"Latina, M. A., Sibayan, S. A., Shin, D. H., Noecker, R. J. & Marcellino, G. Q-switched 532-nm Nd: YAG laser trabeculoplasty (selective laser trabeculoplasty): A multicenter, pilot, clinical study. Ophthalmology 105, 2082\u20132088 (1998).","journal-title":"Ophthalmology"},{"key":"85271_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12886","volume":"19","author":"E Goda","year":"2019","unstructured":"Goda, E., Hirooka, K., Mori, K. & Kiuchi, Y. Intraocular pressure lowering effects of ripasudil: A potential outcome marker for trabeculotomy. BMC Ophthalmol. 19, 243. https:\/\/doi.org\/10.1186\/s12886 (2019).","journal-title":"BMC Ophthalmol."},{"key":"85271_CR19","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2147\/OPTH.S53490","volume":"9","author":"K Leahy","year":"2015","unstructured":"Leahy, K. & Whote, A. Selective laser trabeculoplasty: Current perspectives. Clin. Ophthalmol. 9, 833\u2013841. https:\/\/doi.org\/10.2147\/OPTH.S53490 (2015).","journal-title":"Clin. Ophthalmol."},{"key":"85271_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/IJG.0b013e3181fc8020","volume":"21","author":"M Shibata","year":"2012","unstructured":"Shibata, M. et al. Clinical results of selective laser trabeculoplasty in open-angle glaucoma in Japanese eyes: Comparison of 180 degree with 360 degree SLT. J. Glaucoma. 21, 17\u201321 (2012).","journal-title":"J. Glaucoma."},{"key":"85271_CR21","first-page":"406","volume":"9","author":"A Miraftabi","year":"2016","unstructured":"Miraftabi, A., Nilforushan, N., Nassiri, N. & Nouri-Mahdavi, K. Selective laser trabeculoplasty in patients with pseudoexfoliative glaucoma vs primary open angle glaucoma: A one-year comparative study. Int. J. Ophthalmol. 9, 406\u2013410 (2016).","journal-title":"Int. J. Ophthalmol."},{"key":"85271_CR22","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1007\/s12325-016-0389-3","volume":"33","author":"S Sato","year":"2016","unstructured":"Sato, S., Hirooka, K., Nitta, E., Ukegawa, K. & Tsujikawa, A. Additive intraocular pressure lowering effects of the Rho kinase inhibitor, ripasudil in glaucoma patients not able to obtain adequate control after other maximal tolerated medical therapy. Adv Ther. 33, 1628\u20131634 (2016).","journal-title":"Adv Ther."},{"key":"85271_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/IJG.0000000000000552","volume":"26","author":"H Inazaki","year":"2017","unstructured":"Inazaki, H. et al. Efficacy of the additional use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. J. Glaucoma. 26, 96\u2013100 (2017).","journal-title":"J. Glaucoma."},{"key":"85271_CR24","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00417-017-3727-5","volume":"255","author":"H Inazaki","year":"2017","unstructured":"Inazaki, H. et al. One-year efficacy of adjunctive use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. Graefes. Arch. Clin. Exp. Ophthalmol. 255, 2009\u20132015 (2017).","journal-title":"Graefes. Arch. Clin. Exp. Ophthalmol."},{"key":"85271_CR25","first-page":"93","volume":"38","author":"K Inoue","year":"2018","unstructured":"Inoue, K., Okayama, R., Shiokawa, M., Ishida, K. & Tomita, G. Efficacy and safety of adding ripasudil to existing treatment regiments for reducing intraocular pressure. Int. Ophthalmol. 38, 93\u201398 (2018).","journal-title":"Int. Ophthalmol."},{"key":"85271_CR26","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","volume":"156","author":"H Tanihara","year":"2013","unstructured":"Tanihara, H. et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am. J. Ophthalmol. 156, 731\u2013736 (2013).","journal-title":"Am. J. Ophthalmol."},{"key":"85271_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12325-018-0863-1","volume":"36","author":"H Tanihara","year":"2019","unstructured":"Tanihara, H. et al. Safety and Efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 3-month interim analysis of ROCK-J, a post-marketing surveillance study. Adv. Ther. 36, 333\u2013343 (2019).","journal-title":"Adv. Ther."},{"key":"85271_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598","author":"A Futakuchi","year":"2020","unstructured":"Futakuchi, A. et al. Intraocular pressure-lowering effects of ripasudil in uveitic glaucoma, exfoliation glaucoma, and steroid-induced glaucoma patients: ROCK-S, a multicenter historical cohort study. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598 (2020).","journal-title":"Sci. Rep."},{"key":"85271_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/IJG.0b013e3181752c97","volume":"18","author":"N Prasad","year":"2009","unstructured":"Prasad, N., Murthy, S., Dagianis, J. J. & Latina, M. A. A comparison of the intervisit intraocular pressure fluctuation after 180 and 360 degrees of selective laser trabeculoplasty (SLT) as a primary therapy in primary open angle glaucoma and ocular hypertension. J. Glaucoma. 18, 157\u2013160 (2009).","journal-title":"J. Glaucoma."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85271-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85271-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85271-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:07:56Z","timestamp":1670044076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85271-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["85271"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-85271-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"12 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5812"}}